Umeå based QureTech Bio has appointed Markus Thor as CEO, succeeding Helén Fält. With 30 years of pharmaceutical experience, Thor aims to advance the life science company's pipeline toward clinical trials, focusing on solutions for antimicrobial resistance.
Christian Hedberg, a professor at Umeå University, is developing a revolutionary drug to treat cryptosporidiosis in animals and humans. He collaborates with France's INRAE and the treatment has shown promising results in ruminant models and has the potential to address a significant global health issue. Christian Hedberg has joined Umeå Biotech Incubator to bring the treatment to the market.
HiloProbe, based in Umeå, secures SEK 3 million in funding from existing owners for sales initiation. The capital injection aims to attract more investment and reach a break-even point. The company is close to a breakthrough with ColoNode, a reagent kit for analyzing lymph nodes in colorectal cancer patients.
Umeå secures 1.8 million (22 SEK million) in EU funding for life science projects to boost innovation and industry growth. The project "Life Science City" is run by Umeå Biotech Incubator and seeks to expand the sector and strengthen collaborations. The SOLH project is a joint effort between Västerbotten and Norrbotten aiming to streamline and unify the innovation system.
MetaCurUm Biotech AB plans to raise 100 million SEK following founder Maréne Landström being named Sweden's Cancer Researcher of the Year. Their groundbreaking cancer treatment, still in the preclinical phase, aims to halt the TGFβ pathway cancer cells utilize. The Umeå based company is collaborating with international researchers and exploring biomarkers for patient stratification.
Mucocort AB has received approval to start a clinical trial for an intraoral patch (M045A) to treat aphthous stomatitis, a condition causing mouth ulcers. The patch aims for immediate pain relief and healing promotion. The trial will be conducted in collaboration with Oral Care AB and produced by Aurena Laboratories AB in Sweden.
The Umeå company SpinChem has joined the Enzyme Technology Alliance, a group of six European companies collaborating to bring competitive solutions to the biotech industry. CEO Emil Byström states the alliance can offer solutions unimaginable before, aiming to replace harmful processes with environmentally friendly alternatives and contribute to a more sustainable industry.
The Umeå Lab Fair, organized by Umeå Biotech Incubator, will take place on April 25th with 18 participating companies showcasing the latest developments in the life science industry. The new fair targets regional laboratory personnel and fills a gap in Umeå's event calendar. A Life Science Pub at Cinco will follow the fair, providing a networking opportunity for exhibitors and attendees.
The Vinnova project BRIDGE Sweden is receiving a 7.7 million SEK investment to streamline the transition from research to commercialization of biological pharmaceuticals and precision medicine. The initiative aims to integrate research infrastructure with innovation systems, develop new cell lines on SciLifeLab's DDD platform, and enhance Sweden's global position in drug development.
Diamyd Medical is expanding its workforce in Umeå, hiring individuals with key competencies for the production of technical batches of recombinant GAD65 protein. The company's biomanufacturing facility in Umeå is established for the production of Diamyd, currently being evaluated in a Phase III clinical trial for preserving insulin production.
Umeå Municipality is targeting 500 new Life science jobs, aiming to attract major companies to the region. With a focus on expanding the industry, utilizing the academic resources of Umeå University, and promoting diversity, the municipality is working towards a thriving Life science sector by 2030.
Umeå Biotech Incubator has been named one of "Europe's leading Start-Up Hubs" by Financial Times, Statista, and Sifted. "This is an acknowledgment that our efforts are competitive, even globally," says Peter Jacobsson, UBI's operation coordinator.
Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.
Tvistevägen 48C
907 36 Umeå
Sweden